Brief: Keros Therapeutics To Develop Ker-065 For The Treatment Of Obesity
03/01/2024 13:17
Jan 3 (Reuters) - Keros Therapeutics Inc KROS.O :
* KEROS THERAPEUTICS TO DEVELOP KER-065 FOR THE TREATMENT OF
OBESITY
* EXPECTS TO REPORT INITIAL DATA FROM THIS PHASE 1 CLINICAL
TRIAL
IN Q1 OF 2025
* PRECLINICAL DATA SHOWED POTENTIAL PROOF-OF-MECHANISM OF
KER-065
FOR TREATMENT OF OBESITY
Source text for Eikon: ID:nGNX7zJn1h
Further company coverage: KROS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops